符合与不符合SWOG白血病研究入选标准患者的结局相当
分析2005年以来13项SWOG白血病委员会方案中2361例入组患者,247例(10%)被判定不符合入选标准,其中169例纳入分析。不符合与符合标准患者基线特征相似,ECOG体能状态≥2比例、5级严重不良事件发生率及总生存均无显著差异,完全缓解率除S0325和S0703外相似。作者认为非关键性入选标准可放宽,以扩大入组并避免方案偏离。
要点
- 13项SWOG白血病方案共入组2361例,247例(10%)不符合入选标准,169例纳入分析。
- 不符合与符合标准患者ECOG体能状态≥2比例(P=0.12)及5级严重不良事件率(P=0.62)无显著差异。
- 两组总生存无差异(P=0.25),完全缓解率除S0325(P<0.001)和S0703(P=0.004)外相似。
核心结论
- 非关键性入选标准可放宽,从而扩大患者入组并避免方案偏离。
研究设计与样本
- 分析2005年以来开放的13项西南肿瘤协作组(SWOG)白血病委员会2期、2/3期或3期方案,共入组2361例患者,评估入选资格状态、不符合原因、基线特征、ECOG体能状态、严重不良事件、完全缓解状态和总生存。
主要发现
- 247例(10%)被判定不符合入选标准,其中78例被排除分析,169例纳入分析。
- 纳入分析的169例中,60%(101/169)因基线记录缺失被排除。
- 不符合与符合标准患者基线特征相似,例外为S0325(P=0.02)和S0530(P=0.002)的ECOG体能状态。
- 多变量分析中,ECOG体能状态≥2的患者比例(P=0.12)和5级严重不良事件发生率(P=0.62)在两组间无差异。
- 符合与不符合标准患者总生存无差异(P=0.25),完全缓解率除S0325(P<0.001)和S0703(P=0.004)外相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients may be deemed ineligible for a clinical trial for reasons that do not directly impact efficacy or safety. We identified reasons for ineligibility and compared outcomes of ineligible with eligible patients treated on Southwest Oncology Group (SWOG) Leukemia Committee protocols. Patients enrolled in SWOG phase 2, 2/3, or 3 protocols open since 2005 were analyzed for eligibility status, reasons for ineligibility, baseline characteristics, Eastern Cooperative Oncology Group (ECOG) performance status (PS), serious adverse events (SAEs), complete remission (CR) status, and overall survival. A total of 2361 patients were enrolled in the 13 included studies. Of these, 247 (10%) were deemed ineligible; 78 were excluded from analyses, and 169 were included. Of the 169 included in analyses, 60% (101/169) were excluded due to missing baseline documentation. Baseline characteristics comparing ineligible to eligible patients were similar, with the exception of ECOG PS for S0325 (P = .02) and S0530 (P = .002). In multivariable analyses, neither the proportion of patients with ECOG PS ≥ 2 (P = .12) nor the rate of grade 5 SAEs (P = .62) differed between groups. There was no difference in survival between eligible and ineligible patients (P = .25), and CR rates were similar, with the exception of S0325 (P < .001) and S0703 (P = .004). The findings of this study suggest that nonessential eligibility criteria can be less restrictive, thus expanding patient enrollment and avoiding protocol deviations. The clinical trials included in this study were registered at www.clincialtrials.gov as #NCT00085709, #NCT00066794, #NCT00070499, #NCT00109837, #NCT00093418, #NCT00492856, #NCT00337168, #NCT00352365, #NCT00658814, #NCT00792948, #NCT00945815, #NCT00840177, and #NCT01522976.
引用
- Statler A, Othus M, Erba HP, et al. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood. 2018. PMID: 29618479. doi:10.1182/blood-2018-01-826693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。